Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

ENT Disorder Treatment Market – Hear Better, Breathe Better, Live Better

ENT also known as otolaryngology is a stream of medical science that deals with disorders associated with ear, nose, and throat. Diseases related to ears, throat, and nose significantly affect the quality of life and could lead to surgeries in few cases such as chronic tonsillitis, ear infections, and severe sinusitis problems as well as cancers of the throat or larynx, and others. In order to treat these disorders, ENT treatment is required. These diseases can either be treated with the help of devices or drugs, however, surgeries are recommended to patients with severe disease cases. Surgical procedures are required in few cases such as throat cancer as recommended by otolaryngologist, however, an oncologist performs the tumor removal procedures, which is either followed by a radiation or chemotherapy, depending on the severity.

The global ENT disorder treatment market was valued at US$ 9,521.1 million in 2016 and is expected to witness a robust CAGR of 3.22% over the forecast period (2017–2025).

Figure 1. Global ENT Disorder Treatment Market Value (US$ Mn), by Region, 2016

ent disorder treatment market

US$ 3,345.71 Mn

Source: Coherent Market Insights (2018)

Increasing air and noise pollution is expected to aid in growth of ENT disorder treatment market

One of major factors leading to rise in number of ENT diseases is increasing air and noise pollution as well as bacterial concentration in the environment leading to various infections. According to the World Health Organization, 2017, around 40% of the European population is exposed to road traffic noise levels exceeding 55dB, leading to chronic hearing diseases such as loss of hearing, and earache. Moreover, air pollution can lead to throat infections as well as nasal infections leading to sinusitis and other disorders. According to the Centers of Disease Control and Prevention (CDC) 2017, around 25% of all hearing loss cases are due to noise and sound caused due to environmental pollution termed as Noise Induced Hearing Loss (NIHL). Moreover, excessive smoking can also lead to throat diseases leading to cancer. According to the American Cancer Society, 2013, around 26,000 people living in the U.S. were diagnosed with cancer of the larynx and throat due to tobacco smoking and consumption. Several other factors leading to growth of ENT disorder treatment market include high investments in R&D for development of ENT diseases treatment, especially for rhinitis; growing cases of bacterial diseases, and others. However, side effects and high cost of treatment coupled with low awareness about treatment for ENT disorders are factors expected to negatively affect growth of the market growth.

New development of antibiotics and increasing approvals of antibiotics would provide opportunities for the market growth over the forecast years. For instance, in April 2014, FDA approved Grastek (Timothy Grass Pollen Allergen Extract) for the treatment of pollen induced allergic rhinitis developed by Merck.

North America is expected to be dominant in the global ENT disorder treatment market over the forecast period. This is attributed to major presence of key players and increasing focus towards enhancing existing treatment options. For instance, in December 2017, Intersect ENT, Inc. — a U.S.-based company — received FDA approval for Sinuva (mometasone furoate) sinus implant as a treatment option for patients suffering from recurrent nasal polyps. Asia Pacific market is expected to witness a significant growth, owing to increasing awareness among people regarding availability of medical treatments for ENT disorders as well as expansion of key vendors in Asian countries by setting up new manufacturing and distribution facilities. For instance, in October 2017, GlaxoSmithKline — a major pharmaceutical player — opened Asia Headquarters in One-North Singapore.

Development of new therapies and product launches are factors expected to boost the market growth

The recent past has witnessed a number of product approvals from the U.S. Food and Drug Administration (FDA) for ENT diseases, as a result of continuous R&D, to offer effective and efficient treatment options. For instance, in December 2015, Otonomy, Inc. — a U.S.-based company — received FDA approval for commercialization of its new antibiotic OTIPRIO (ciproflaxin otic suspension) for treatment of pediatric patients with bilateral otitis media. Key players are also focusing on inorganic strategies such as merger and acquisitions for enhancement of research department as well as commercialization of products in terms of sales and marketing. For instance, in July 2017, Entellus Medical announced a definitive agreement to acquire Spirox, Inc. a privately held ENT medical technology that develops, manufactures and markets absorbable nasal implants and other medical devices.

Key players operating in the global ENT disorder treatment market include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.

Factors such as sinusitis and aging, affects normal functioning of ear, nose and throat. ENT is one of the most important branches of medical science, also known as otolaryngology, which is focused on diagnosis and treatment of disorders associated with ear, nose, and throat. Dysfunction of these organs may affect the person’s quality of life. Disorders related to ENT are treated with the help of devices as well as various classes of drugs. The report mainly covers drug classes and medical devices used for the treatment of disease such as sinusitis, rhinitis, otitis media, tonsillitis, and others.

Market Dynamics

Major factor contributing to growth of the global ENT disorder treatment market includes increasing pollution. For instance, according to the World Health Organization 2015, over 4 million children die each year, globally due to environmental causes such as pollution and pollen grain infections. Several other factors contributing to the market growth includes, increasing R&D for drugs for treatment of ENT, and rising geriatric population and others. Rising awareness about the ENT treatments in emerging economies would increase the opportunities for market players to invest and capitalize in such regions. Asia Pacific is expected to witness significant traction in the global ENT disorder treatment market over the forecast period. This is owing to focus of key players on geographical expansion in the region and increasing R&D in ENT by various educational and research institutes in collaboration with local players. However, low awareness about the availability of treatments in some emerging economies such as several African countries as well as threat of developing antibiotic resistance are factors that are expected to hinder the market growth.

Key features of the study:

  • This report provides in-depth analysis of global ENT disorder treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global ENT disorder treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddy’s Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global ENT disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the ENT disorder treatment market

Detailed Segmentation:

  • Global ENT Disorder Treatment Market, By Treatment Type:
    • By Devices
      • Hearing Aid Devices
      • Voice Prostheses
      • Nasal Splints
      • Hearing Implants
      • Others
    • By Drugs
      • Antibiotics
      • Antihistamines
      • Steroids
      • Anti-inflammatory Drugs
      • Others          
  • Global ENT Disorder Treatment Market, By Organ Type:
    • Ears
    • Nose
    • Throat
  • Global ENT Disorder Treatment Market, By End User:
    • Hospitals
    • Clinics
    • Ambulatory Surgical Centers
    • Home Care Settings
    • Others
  • Global ENT Disorder Treatment Market, By Geography:
    • North America
      • By Treatment Type:
        • By Devices
          • Hearing Aid Devices
          • Voice Prostheses
          • Nasal Splints
          • Hearing Implants
          • Others
        • By Drugs
          • Antibiotics
          • Antihistamines
          • Steroids
          • Anti-inflammatory Drugs
          • Others
      • By Organ Type:
        • Ears
        • Nose
        • Throat
      • By End User:
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
        • Home Care Settings
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Treatment Type:
        • By Devices
          • Hearing Aid Devices
          • Voice Prostheses
          • Nasal Splints
          • Hearing Implants
          • Others
        • By Drugs
          • Antibiotics
          • Antihistamines
          • Steroids
          • Anti-inflammatory Drugs
          • Others
      • By Organ Type:
        • Ears
        • Nose
        • Throat
      • By End User:
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
        • Home Care Settings
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment Type:
        • By Devices
          • Hearing Aid Devices
          • Voice Prostheses
          • Nasal Splints
          • Hearing Implants
          • Others
        • By Drugs
          • Antibiotics
          • Antihistamines
          • Steroids
          • Anti-inflammatory Drugs
          • Others
      • By Organ Type:
        • Ears
        • Nose
        • Throat
      • By End User:
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
        • Home Care Settings
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type:
        • By Devices
          • Hearing Aid Devices
          • Voice Prostheses
          • Nasal Splints
          • Hearing Implants
          • Others
        • By Drugs
          • Antibiotics
          • Antihistamines
          • Steroids
          • Anti-inflammatory Drugs
          • Others
      • By Organ Type:
        • Ears
        • Nose
        • Throat
      • By End User:
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
        • Home Care Settings
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment Type:
        • By Devices
          • Hearing Aid Devices
          • Voice Prostheses
          • Nasal Splints
          • Hearing Implants
          • Others
        • By Drugs
          • Antibiotics
          • Antihistamines
          • Steroids
          • Anti-inflammatory Drugs
          • Others
      • By Organ Type:
        • Ears
        • Nose
        • Throat
      • By End User:
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
        • Home Care Settings
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type:
        • By Devices
          • Hearing Aid Devices
          • Voice Prostheses
          • Nasal Splints
          • Hearing Implants
          • Others
        • By Drugs
          • Antibiotics
          • Antihistamines
          • Steroids
          • Anti-inflammatory Drugs
          • Others
      • By Organ Type:
        • Ears
        • Nose
        • Throat
      • By End User:
        • Hospitals
        • Clinics
        • Ambulatory Surgical Centers
        • Home Care Settings
        • Others
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Sanofi *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • AstraZeneca Plc
    • Novartis AG
    • Pfizer, Inc.
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline Plc
    • Otonomy, Inc.
    • Merck & Co., Inc.
    • Reddy’s Laboratories Ltd.
    • Allergen Plc
    • Cochlear, Ltd.
    • Sonova Holdings AG
    • Siemens Healthineers
    • Starkey Laboratories, Inc.
    • William Demant Holdings A/S
    • Widex A/S
    • GN ReSound A/S
    • Sonic Innovations, Inc.
    • Panasonic Corporation
    • Beltone
    • Rexton, Inc.
    • Avada Hearing Care
    • Miracle-Ear, Inc.
    • MED-EL GmbH
    • Nuear Hearing Aids Inc.
    • AudioSync, Inc.
    • Bernafon
    • American Hearing Systems, Inc.
    • Unitron Hearing, Inc.
    • Zounds, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Organ Type
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Key Highlights
    • Reimbursement Scenario
    • Technological Advancements
    • Recent FDA Approvals
    • Regulatory Scenario
    • PEST Analysis
    • Epidemiology
  4. Global ENT Disorder Treatment Market, By Treatment Type, 2017–2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017–2025
      • Segment Trends
    • By Devices
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
      • Segment Trends
        • Hearing Aid Devices
        • Voice Prostheses
        • Nasal Splints
        • Hearing Implants
        • Others
    • By Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
      • Segment Trends
        • Antibiotics
        • Antihistamines
        • Steroids
        • Anti-inflammatory Drugs
        • Others
  5. Global ENT Disorder Treatment Market, By Organ Type, 2017–2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017–2025
      • Segment Trends
    • Ears
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
    • Nose
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
    • Throat
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
  6. Global ENT Disorder Treatment Market, By End User, 2017–2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017–2025
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
    • Ambulatory Surgical Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
    • Home Care Settings
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Million)
  7. Global ENT Disorder Treatment Market, By Region, 2017–2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2025
    • North America
      • Market Size and Forecast, By Treatment Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Organ Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017–2025, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Treatment Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Organ Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017–2025, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Treatment Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Organ Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017–2025, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Organ Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017–2025, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Treatment Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Organ Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017–2025, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Organ Type, 2017–2025, (US$ Million)
      • Market Size and Forecast, By End User, 2017–2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017–2025, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profiles
      • Sanofi*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Pfizer, Inc.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Teva Pharmceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Otonomy, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Dr. Reddy’s Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Allergen Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cochlear Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sonova Holdings AG.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Siemens Healthineers
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Starkey Laboratories, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • William Demant Holdings, A/S
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Widex A/S
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GN Re/Sound A/S
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sonic Innovations. Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Panasonic Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Beltone
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Avada Hearing Care
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
      • Miracle-Ear., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
      • MED-EL GmBH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Nuear Hearing Aids, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • AudioSync, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Bernafon
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
      • American Hearing Systems, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
      • Unitron Hearing, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Zounds, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 42 market data tables and 36 figures on "ENT Disorder Treatment Market - Global forecast to 2025”.

Frequently Asked Questions

The global ENT disorder treatment marketis estimated to surpass US$ 10 Billion by 2025
Major players operating in the global ENT disorder treatment market include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.
Side effects and high cost of treatment, coupled with low awareness about treatment for ENT disordersare some of the major factors that are expected to hamper growth of the market over the forecast period.
Rising air and noise pollution as well as bacterial concentration in the environment leading to various infectionsare some of the major factors that are expected to propel growth of the market over the forecast period
The global ENT disorder treatment market is estimated to exhibit a CAGR of 3.22% over the forecast period.
Among regions, North Americais expected to hold dominant position in the ENT disorder treatment market over the forecast period.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner